Tags : Relapsing

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in

Shots: The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries, 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions […]Read More

Janssen Reports Submission of Ponesimod’s NDA to the US FDA

Shots: The NDA is based on P-III OPTIMUM study assessing ponesimod (20mg) vs Aubagio (teriflunomide, 14 mg) in patients with relapsing MS The P-III OPTIMUM study results: reduction in ARR (30.5%); reduction in CUALs (56%); reduction in fatigue symptoms; safety profile is consistent with the previous studies Ponesimod is an investigational S1P1 modulator, act by […]Read More

Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for

Shots: The P-III OPTIMUM study results involve assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing MS for 108wks. at 162 sites across the globe The P-III OPTIMUM study results: 30.5% reduction in ARR (0.202 vs 0.290); 56% reduction in the number of CUALs; @12wks. CDA (10.1% vs 12.4%); safety […]Read More

Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies

Shots: The P-III OPERA, ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS, presented at AAN Annual Meeting Results: reduction in risk of disability progression associated with exposure and lower B-cell levels & permanent disability progression; @24wks. reduction in CDP; @48wks. RMS, PPMS patients with CDP […]Read More